Abiopharma

🔍 Sawhney Vikrant (Executive)

Company: Blackstone Inc. (BX)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 16,965 shares of Common Stock at $125.55 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: false | shares_owned_after: 912,718.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 13,049 shares of Common Stock at $126.11 per share (Direct)
  Date: 2026-05-01 | Code: S | equity_swap_involved: false | shares_owned_after: 899,669.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: H | nature_of_ownership: See footnote | shares_owned_after: 17,600.00 | Footnotes: F3

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.98, inclusive. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.00 to $126.28, inclusive. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
• F3: Such Blackstone shares are held in a grantor retained annuity trust, for which the Reporting Person serves as investment trustee.
• REMARKS: The Reporting Person disclaims beneficial ownership of the securities reported on this form except to the extent of his pecuniary interest.